THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
THE GENERAL HOSPITAL CORPORATION (USA)
Inventeur(s)
Kleinstiver, Benjamin
Guy, Jacqueline
Bird, Adrian
Abrégé
The present disclosure relates to compositions for use in the treatment of a class of Rett syndrome mutations, namely C-terminal deletions, comprising a base editor to alter a stop codon in a mutant MECP2 gene. This alteration does not return the gene to its wild-type (WT) form, but re-establishes normal levels of a version which is functionally equivalent to a wild¬ type version of the MeCP2 protein.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Doudesis, Dimitrios
Lee, Kuan Ken
Mills, Nicholas Linton
Abrégé
A computer implemented method of providing and an indication of the probability of myocardial infarction using cardiac biomarker measurements comprises combining measured with other clinical indicators in statistical model to compute the probability of a subject having suffered myocardial infarction, the statistical model using a machine learning algorithm. A decision tool and a system for implementing the method are disclosed.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p.ex. pour analyser les cas antérieurs d’autres patients
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Baker, Andrew
Zacchign, Serena
Giacca, Mauro
Abrégé
Disclosed is a cohort of anti-proliferative microRNAs (miRs) wherein each member of the cohort (or combinations thereof) represent a target for modulating cell proliferation (and migration), influencing (or modulating) vascular remodelling and the treatment of various vascular complications, vascular injury vascular disease and (for example) disorders, diseases, syndromes and/or conditions which affect vessels and/or vascular systems of the human or animal body.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
JOHNSON MATTHEY PUBLIC LIMITED COMPANY (Royaume‑Uni)
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Carrick, Andrew
Love, Jason
Morrison, Carole
Oshaugnessy, Paul Noel
Patrick, Jane Helen
Schofield, Emma
Abrégé
A method of selectively extracting rhodium from an aqueous hydrochloric acid solution comprising rhodium and iridium, the method comprising: mixing a first aqueous hydrochloric acid solution comprising rhodium and iridium with an immiscible organic solution comprising a first organic solvent and an extractant system which selectively extracts the rhodium into the organic solution, wherein the first aqueous hydrochloric acid solution has a hydrochloric acid concentration in a range 2 M to 7 M; separating the organic solution comprising the rhodium from the first aqueous hydrochloric acid solution; mixing the separated organic solution with an aqueous stripping solution in order to strip the rhodium from the organic solution into the aqueous stripping solution; separating the organic solution from the aqueous stripping solution; and re-using the organic solution for further extraction of rhodium.
C01G 55/00 - Composés du ruthénium, du rhodium, du palladium, de l'osmium, de l'iridium, ou du platine
C22B 3/26 - Traitement ou purification de solutions, p.ex. de solutions obtenues par lixiviation par extraction liquide-liquide utilisant des composés organiques
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Pollard, Steven
Matjusaitis, Mantas
Abrégé
Disclosed are constructs configured to express adverse (for example cytotoxic and immunomodulatory) payloads in cells, which constructs may be used to treat or prevent recurrent/secondary cancer/tumours and to prime, induce, raise or promote an immune response which is effective against a recurrent/secondary cancer/tumour which might arise from said primary cancer/tumour.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12N 15/67 - Méthodes générales pour favoriser l'expression
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Baker, Andrew
Vacante, Francesca
Abrégé
Disclosed is a construct for use in a method of transcriptional activation of a complex genomic locus. The construct comprises a single guide RNA (sgRNA) binding a regulatory element of the said complex genomic locus, and a deactivated Cas. The construct may be introduced into cells including the genomic locus of interest in order to activate the regulatory element to transcribe multiple transcripts within said complex genomic locus.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Arslan, Tughrul Sati
Saied, Imran Mohammed
Abrégé
The present disclosure relates to a fluid level and/or fluid composition monitoring system (2) comprising a radiofrequency sensor (4) configured to be included in an item of furnishing or other item for use by a patient or other subject and a control system (8) configured to receive a signal from the radiofrequency sensor and to determine a level of fluid and/or a composition of fluid in a part (6a) of a patient or other subject's body (6) in vivo based on the signal.
A61B 5/0507 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio utilisant des micro-ondes ou des ondes térahertz
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Williams, Gareth
Williams, Elvira
Girkin, John
Abrégé
An optical device comprises a plurality of optical components comprising at least one primary mirror and further comprising at least one scanning mirror component and/or at least one spatial light modulator and/or at least one digital mirror, wherein the plurality of optical components are configured to direct light from an input/output module to an objective module and from the objective module to the input/output module and to manipulate a position and/or pattern of the light; and a mono-block structure in which the plurality of optical components is mounted, wherein the mono-block structure is a continuous single structure having walls and a base.
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (Italie)
FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA (Espagne)
INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (Espagne)
KING'S COLLEGE LONDON (Royaume‑Uni)
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Tartaglia, Gian Gaetano
Armaos, Alexandros
Cid, Fernando
Sanchez De Groot, Natalia
Grana-Montes, Ricardo
Pastore, Annalisa
Zacco, Elsa
Horrocks, Mathew
Kantelberg, Owen
Abrégé
The invention relates to a short single-stranded DNA or RNA aptamer that is capable of binding the TDP-43 protein and of detecting all of the different TDP-43 structures individually, from the soluble monomer to the TDP-43 larger aggregates. The aptamer of the invention is also capable of inhibiting aggregation of TDP-43. Because of these properties, the RNA aptamer of the invention is suitable for use in both the diagnosis and therapeutic treatment and prevention of TDP-43-related proteinopathies, such as ALS and FTD.
C12N 15/115 - Aptamères, c. à d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Wood, Harry A C
Stone, James M
Marshall, Adam
Dhaliwal, Kevin
Abrégé
An endoscopic device comprises a wall defining an interior space, a working channel in, or defined by, the interior space, and at least one optical fibre embedded or otherwise provided in the wall, wherein the endoscopic device has an outer diameter of less than 2.5 mm.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
11.
RECOMBINANT THERAPEUTIC FMR1 CONSTRUCTS AND METHODS OF TREATING FRAGILE X SYNDROME AND RELATED DISORDERS
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Henderson, Robert
Abrégé
A macropixel is disclosed. The macropixel comprises a plurality of pixels, each pixel comprising a Single Photon Avalanche Diode (SPAD). The macropixel also comprises a memory configured to store: a plurality of counts, each count associated with a pixel of the plurality of pixels; and a plurality of saturation bits, each saturation bit associated with a count of the plurality of counts. The macropixel also comprises saturation detection circuitry configured to gate a recharge of each SPAD based on a state of the respective saturation bit.
H04N 25/773 - Circuits de pixels, p.ex. mémoires, convertisseurs A/N, amplificateurs de pixels, circuits communs ou composants communs comprenant des convertisseurs A/N, V/T, V/F, I/T ou I/F comprenant des circuits de comptage de photons, p. ex. des diodes de détection de photons uniques [SPD] ou des diodes à avalanche de photons uniques [SPAD]
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Robertson, Ben
Haisch, Michael
Morozov, Alexander
Abrégé
The invention relates to an ophthalmological viscoelastic composition comprising an aqueous solution having a viscoelastic base component and having an additive including at least one water-soluble polymer without covalent bonding to the base component. The additive increases an extensional viscosity of the composition compared to the composition without additive. In addition, the additive is present in a concentration equal to or lower than a concentration of the base component in the aqueous solution.
UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Poradosu, Enrique
Unciti-Broceta, Asier
Abrégé
The disclosure is in part directed to a method of treating a cancer, e.g., a B-cell cancer, in a patient in need thereof, comprising administering to the patient an effective amount of a disclosed tyrosine kinase inhibitor. In some embodiments, the cancer harbors a BTK mutation.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Dunn, Katherine
Speakman, Alexander
Abrégé
A nucleic acid molecule for controllable gene expression comprises: a double-stranded section, comprising a sequence for expression; and a single-stranded overhanging section configured to bind to the double-stranded section to form a nucleic acid triplex.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
16.
METHOD OF DETECTING CLONAL HAEMATOPOIESIS OR CANCER OR PERFORMING ANTENATAL SCREENING AND KITS
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (Royaume‑Uni)
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Psaila, Bethan
Mead, Adam
Gregory, Christopher
Abrégé
The present invention relates to the detection of disease states such as clonal haematopoiesis and cancer as well as fetal screening by analysing thrombocytes for disease associated markers. The methods comprises steps of providing a biological sample comprising thrombocytes; extracting nucleic acid from said biological sample; analysing said nucleic acid to identify the presence of one or more clonal haematopoiesis associated mutations or cancer associated nucleic acid fragments; and indicating the presence or prognosis of clonal haematopoiesis or cancer based on the presence of one or more clonal haematopoiesis associated mutations or cancer associated nucleic acid fragments; or or analysing the nucleic acids for genetic information related to the foetus.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Yang, Yunjie
Giorgio-Serchi, Francesco
Hu, Delin
Abrégé
A sensing device comprising: a plurality of electrodes configured to be distributed about one or more surfaces of a deformable object, wherein the plurality of electrodes are operable to generate capacitance signal output from a plurality of selected pairings of the plurality of electrodes, wherein the plurality of electrodes are distributed about the one or more surfaces of a deformable object such that the plurality of selected pairings comprise at least one proximate pairing and at least one non-proximate pairing, wherein the generated capacitance signal output for a pairing of electrodes is dependent on at least one of: a distance between the electrodes; shape and/or orientation of the electrodes and at least one property of the material between the pairing.
G01B 7/16 - Dispositions pour la mesure caractérisées par l'utilisation de techniques électriques ou magnétiques pour mesurer les déformations dans un solide, p.ex. au moyen d'une jauge de contrainte à résistance
G01L 1/14 - Mesure des forces ou des contraintes, en général en mesurant les variations de la capacité ou de l'inductance des éléments électriques, p.ex. en mesurant les variations de fréquence des oscillateurs électriques
G01L 5/22 - Appareils ou procédés pour la mesure des forces, du travail, de la puissance mécanique ou du couple, spécialement adaptés à des fins spécifiques pour la mesure de la force appliquée aux organes de commande, p.ex. organes de commande des véhicules, détentes
G01D 5/24 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensible; Moyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminé; Transducteurs non spécialement adaptés à une variable particulière utilisant des moyens électriques ou magnétiques influençant la valeur d'un courant ou d'une tension en faisant varier la capacité
18.
RECOMBINANT OPTIMIZED MECP2 CASSETTES AND METHODS FOR TREATING RETT SYNDROME AND RELATED DISORDERS
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Cobb, Stuart Robert
Ross, Paul
Hector, Ralph David
Abrégé
The disclosure provides for optimized therapeutic MECP2 polynucleotide constructs utilized for replacing or compensating for the loss of MeCP2 function in patients with Rett Syndrome. Suitably, the disclosure provides gene therapy cassettes to enable better regulatory control of the MeCP2 protein, including tunable systems that allow MECP2 gene therapy to be expressed at a desired moderate level and demonstrate expression of the vector-derived transgene within a window that alleviates the disease-causing genetic deficiency without producing undesired side effects including overexpression toxicity.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Venugopalan Nair Jalajakumari, Aravind
Mullins, John
Henderson, Robert
Marsden, Edward
Abrégé
The present invention relates to a digital silicon photomultiplier, methods of operating a digital silicon photomultiplier and a device comprising one or more digital silicon photomultipliers. The digital silicon photomultiplier may comprise at least one least one pixel, wherein each pixel includes at least one single photon avalanche photodiode and a toggle operatively connected to each of the at least one single photon avalanche photodiodes. The toggle may output at least one transition wherein each transition represents a detection of a photon. A programmable divider may be operatively connected to each pixel, wherein each programmable divider is programmed with a divisor and each programmable divider receives a first set of transitions and outputs a second set of transitions, wherein each transition in the first set of transitions represents a detection of a photon by a single photon avalanche photodiode of a respective pixel and each transition of the second set of transitions represents a number of detected photons of the respective pixel equivalent to the divisor.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Gilbert, Nick Gilbert
Kleinjan, Dirk
Marsh, Joseph
Kearns, Patrick
Abrégé
A method of identifying stable peptides from a protein, said method comprising: obtaining a peptide from a protein; comparing a solvent-accessible surface area (SASA) of the peptide with a SASA of a corresponding peptide region within the protein; using a result of the comparison to determine whether or not the peptide is structurally stable relative to the corresponding peptide region within the protein. Also disclosed is use of the method to identify stable immunogenic epitopes of SARS-CoV-2, and methods of detecting an antibody response.
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Akram, Ahsan
Megia-Fernandez, Alicia
Mathieson, Layla
Abrégé
The present disclosure relates to the development of novel constructs that are specifically cleaved by fibroblast activation protein-α (FAP) and uses thereof in assays for detecting FAP. Particular constructs include a fluorescence resonance energy transfer (FRET) probe comprising a fluorescent moiety and a quencher moiety attached to a FAP cleavable peptide sequence and optionally including a solubilising moiety, which may be a polyethylene glycol (PEG) derivative.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Seth, Sohan
Abrégé
A method of performing Raman spectroscopy comprising: generating wavelength shifted excitation light for exciting a Raman response from at least one sample, wherein the wavelength shifted excitation light comprises at least two excitation wavelengths; providing the wavelength shifted excitation light to the at least one sample and collecting signal light from the at least one sample; obtaining response signals from the collected signal light; processing the obtained response signals to determine a Raman response and a fluorescence response, wherein determining the Raman response uses at least one characteristic of an expected Raman response to the wavelength shifted excitation light and wherein determining the fluorescence response uses at least one characteristic of an expected fluorescence response to the shifted excitation light.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Wallace, Stephen
Era, Yuta
Dennis, Jonathan Andrew
Hamilton, Louise
Abrégé
The present disclosure relates to a method of coupling a first carbon atom with a second carbon atom to form a C-C bond and a kit suitable for said method. The method comprises contacting carbon atoms with microbially supported metal nanoparticles. The microbially supported metal nanoparticles are prepared by contacting metal reducing microbes with a source of metal under anaerobic conditions and the carbon atoms and microbially supported metal nanoparticles are contacted in a liquid in the presence of a surfactant. The kit comprises microbially supported metal nanoparticles prepared by contacting metal reducing microbes with a source of metal under anaerobic conditions; and a surfactant.
C07C 41/30 - Préparation d'éthers par des réactions ne formant pas de liaisons sur l'oxygène de la fonction éther par augmentation du nombre d'atomes de carbone, p.ex. par oligomérisation
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
SINGAPORE-MIT ALLIANCE FOR RESEARCH & TECHNOLOGY CENTRE (Singapour)
Inventeur(s)
Horne, Andrew Wemyss
Lee, Yie Hou
Saunders, Philippa Tansy Kemp
Abrégé
There is disclosed a method of aiding diagnosis of endometriosis in a female subject. The method comprises comparing a level of 2-methyladenosine detected in a biological sample obtained from the female subject with a baseline level of 2-methyladenosine. There is also disclosed a method of aiding the assessment of endometriosis treatment in a female subject identified as having endometriosis..
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
25.
GENETIC RESISTANCE TO VIRAL DISEASE IN SALMONID FISH
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Houston, Ross
Pavelin, Jonathan Andrew
Sanchez, Diego Robledo
Jin, Yehwa
Abrégé
The present disclosure relates to methods of screening salmonids for increased resistance to viral infection, such as infectious pancreatic necrosis virus (IPNV) infection. The present disclosure also relates to fish which have been genetic modified to have increased resistance to viral/IPNV infection. The present disclosure further relates to the use of these fish, which have been identified, or genetically modified to have increased genetic resistance, in aquaculture breeding programs and/or production. The present disclosure further relates to the use of small molecules which target NAE1 and their use in therapy or prevention of viral/IPNV infection.
C07K 14/46 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Temps, Carolin
Croke, Stephen
O. Carragher, Neil
Unciti-Broceta, Asier
Abrégé
1211113245672n2p2q282r921022, alkoxy, aryloxy, alkylamino, arylamino, carboxyl and carboxamide; R41111 are each independently selected from a group consisting of alkyl, alkenyl and aryl; and n is selected from a group consisting of 0, 1, 2, 3, 4, 5 and 6, p is selected from a group consisting of 0, 1, 2, 3, 4, 5 and 6, q is selected from a group consisting of 0, 1, 2, 3, 4, 5 and 6, and r is selected from a group consisting of 0, 1, 2, 3, 4, 5 and 6. The disclosure also relates to pharmaceutical compositions, therapeutic uses and process for preparing the compound of the disclosure.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Roy, Dipa
Ó Brádaigh, Conchúr
O'Rourke, Kate Niamh
Obande, Ogwa Winifred
Abrégé
A method comprises providing a thermoplastic polymer composite article (100) comprising a thermoplastic polymer, wherein the thermoplastic polymer is an addition polymer derived from at least one first addition monomer; contacting a portion of the article with a solvent-free composition comprising at least one polymerisable compound, the at least one polymerisable compound comprising at least one second addition monomer; and polymerising the composition at ambient temperature, wherein the at least one polymerisable compound does not include a polymer.
B05D 7/02 - Procédés, autres que le flocage, spécialement adaptés pour appliquer des liquides ou d'autres matériaux fluides, à des surfaces particulières, ou pour appliquer des liquides ou d'autres matériaux fluides particuliers à des substances macromoléculaires, p.ex. à du caoutchouc
B29C 73/02 - Réparation d'articles faits de matières plastiques ou de substances à l'état plastique, p.ex. d'objets façonnés ou fabriqués par utilisation de techniques couvertes par la présente sous-classe ou la sous-classe utilisant un liquide ou un matériau pâteux
B29C 65/48 - Assemblage d'éléments préformés; Appareils à cet effet en utilisant des adhésifs
B32B 37/00 - Procédés ou dispositifs pour la stratification, p.ex. par polymérisation ou par liaison à l'aide d'ultrasons
C08J 5/12 - Fixation d'un matériau macromoléculaire préformé au même matériau ou à un autre matériau compact, tel que du métal, du verre, du cuir, p.ex. en utilisant des adhésifs
C08J 7/06 - Revêtement par des compositions ne contenant pas de substances macromoléculaires
28.
METHOD OF SELECTIVE PRECIPITATION OF METALS USING AMIDE COMPOUNDS
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Love, Jason
Morrison, Carole
Kinsman, Luke
Ngwenya, Bryne T.
Abrégé
12344 are each independently a substituted or unsubstituted aryl group or a substituted or unsubstituted C1-C8 hydrocarbyl group; and Z is a C2-C6 hydrocarbyl group or an aryl group.
C07C 323/60 - Thiols, sulfures, hydropolysulfures ou polysulfures substitués par des halogènes, des atomes d'oxygène ou d'azote ou par des atomes de soufre ne faisant pas partie de groupes thio contenant des groupes thio et des groupes carboxyle liés au même squelette carboné ayant les atomes de soufre des groupes thio liés à des atomes de carbone acycliques du squelette carboné avec l'atome de carbone d'au moins un des groupes carboxyle lié à des atomes d'azote
C22B 3/16 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés par lixiviation dans des solutions organiques
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Al Abbas, Tarek
Henderson, Robert
Abrégé
A Light Detection and Ranging (LIDAR) circuit includes a non-transitory memory device comprising a first memory and a second memory, and at least one control circuit. The at least one control circuit is configured to execute first memory storage operations to store data indicated by detection signals received from one or more photodetector elements in the first memory during a time between pulses of an emitter signal output from a LIDAR emitter element, and execute second memory storage operations to include previous data indicated by previous detection signals received from the one or more photodetector elements, which was stored in the first memory, in respective memory bins of the second memory. The first and second memory storage operations are executed at least partially concurrently. Related devices and methods of operation are also discussed.
G01S 7/4863 - Réseaux des détecteurs, p.ex. portes de transfert de charge
G01S 17/26 - Systèmes déterminant les données relatives à la position d'une cible pour mesurer la distance uniquement utilisant la transmission d'ondes à modulation d'impulsion interrompues dans lesquels les impulsions transmises utilisent une onde porteuse modulée en fréquence ou en phase, p.ex. pour la compression d'impulsion des signaux reçus
G01S 17/89 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour la cartographie ou l'imagerie
G01S 17/931 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour prévenir les collisions de véhicules terrestres
UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (Royaume‑Uni)
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Maciejczyk, Michal
Zysman-Colman, Eli
Robertson, Neil
Abrégé
The invention relates to spiro-(fluorene-9,9'-(thio)xanthene)-based compounds (I) and a process for the preparation of these. The compounds are useful as thermally activated delayed fluorescence material in electroluminescent devices such as organic light-emitting diodes (OLEDs). The invention extends to electroluminescent devices comprising one or more of these compounds as an emitter and a host material.
C07F 9/6547 - Cycles à six chaînons condensés avec des carbocycles ou des systèmes carbocycliques
C07F 9/655 - Composés hétérocycliques, p.ex. contenant du phosphore comme hétéro-atome du cycle comportant des atomes d'oxygène, avec ou sans atomes de soufre, de sélénium ou de tellure, comme uniques hétéro-atomes du cycle
H01L 51/00 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Vendrell, Marc
Scott, Jamie I.
Gordon, Doireann
Abrégé
The present disclosure relates to the development of novel cleavable peptide probes for use in detecting granzyme B, as well as methods for using the probes in medical and biological settings. The probes may comprise a fluorescent moiety conjugated or bound to the peptide, and quencher moiety conjugated or bound to the peptide and upon cleavage of the peptide, the fluorescent moiety becomes dequenched.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Mahon, Stephen
Stokes, Adam
Abrégé
A hydraulic demultiplexer or multiplexer for providing hydraulic actuation of a plurality of robotic components wherein the hydraulic demultiplexer or multiplexer comprising an arrangement of hydraulically-controlled and hydraulically-operated valves.
F15C 3/02 - Eléments de circuits ayant des parties en mouvement utilisant des clapets à bobines
F15C 4/00 - Eléments de circuits caractérisés par leurs fonctions particulières
F15C 5/00 - Fabrication des éléments de circuits de fluide; Fabrication des assemblages de ces éléments
F15B 13/042 - Dispositifs de distribution ou d'alimentation du fluide caractérisés par leur adaptation à la commande de servomoteurs pour utilisation avec un servomoteur unique actionnés par la pression du fluide
F15B 11/20 - Systèmes de servomoteurs dépourvus d'asservissement avec plusieurs servomoteurs commandant plusieurs organes réagissant les uns sur les autres ou fonctionnant successivement
F15B 13/07 - Dispositifs de distribution ou d'alimentation du fluide caractérisés par leur adaptation à la commande de servomoteurs pour utilisation avec plusieurs servomoteurs opérant en séquences distinctes
F15B 20/00 - Dispositions propres à la sécurité pour systèmes de manœuvre utilisant les fluides; Utilisation des dispositifs de sécurité dans les systèmes de manœuvre utilisant des fluides; Mesures d'urgence pour les systèmes de manœuvre utilisant des fluides
33.
A SYSTEM COMPRISING A NEMATIC LIQUID CRYSTAL AND AN INTERFACE
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Wood, Tiffany
Abrégé
A system comprising: a nematic liquid crystal, and at least one interface in contact with the nematic liquid crystal, wherein the interface comprises a first interface region on one side of the nematic liquid crystal and a second interface region on another side of the nematic liquid crystal, the interface comprising nucleation sites to form defect lines in the nematic liquid crystal extending across the nematic liquid crystal from the first interface region to the second interface region.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Bradley, Mark
Geng, Jin
Neumann, Kevin
Zhang, Yichuan
Abrégé
The present disclosure describes a novel class of masking agents that can be activated under ionising radiation. The masking agents (which in some cases may be referred to as protecting groups) can be conjugated, linked or bonded to a parent compound to provide a masked compound and ionising radiation can be used to activate the masking agent to release the parent compound. These masking agents or protecting groups may find application in a wide variety of fields, and may be particularly useful in therapy, e.g. in the formation of prodrugs and as linkers in antibody drug conjugates.
C07C 247/16 - Composés contenant des groupes azido avec des groupes azido liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné
C07C 247/18 - Composés contenant des groupes azido avec des groupes azido liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné étant substitué de plus par des groupes carboxyle
C07C 311/49 - Amides d'acides sulfoniques, c. à d. composés comportant des atomes d'oxygène, liés par des liaisons simples, de groupes sulfoniques remplacés par des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes sulfonamide liés de plus à un autre hétéro-atome à des atomes d'azote
C07D 311/16 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre liés directement en position 2 non hydrogénés dans l'hétérocycle substitués en position 7
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Kuo, Richard Izen
Abrégé
The present invention relates to methods, kits and compositions for selective amplification of single stranded DNA. The invention is useful in generating a normalized cDNA fraction and it can be used in various RNA and DNA sequencing applications to amplify DNA templates having pre-attached adapters. We describe a method of selective amplification of single stranded cDNA. We also describe an oligonucleotide dimer composition for use in a method and a selective amplification kit for selectively amplifying low abundance cDNA from a cDNA sample.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Gonzalez, Agustin Barria
Benzie, John
Houston, Ross Houston
Abrégé
The present disclosure relates to methods of screening tilapia for increased genetic resistance to viral infection, such as Tilapia Lake Virus, as well as the use of these fish, which have been identified as having increased genetic resistance, in aquaculture breeding programs and production.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE (ILRI) (Kenya)
SCOTLAND'S RURAL COLLEGE (SRUC) (Royaume‑Uni)
Inventeur(s)
Prendergast, James
Wragg, David
Toye, Philip
Cook, Elizabeth
Stitt, Tatjana
Abrégé
The present invention relates to tolerance to theileriosis infection in cattle. In particular, the present invention relates to methods and kits for determining predisposition in bovine animals to tolerance to Theileria parasite infection, especially by identifying at least one genetic marker indicative of tolerance. The present invention also relates to methods of selective breeding of cattle to select for individuals with a predisposition to tolerance to Theileria infection. A subject animal is determined to have a predisposition to tolerance to theileriosis infection if the presence of at least one variant is identified in a tolerance region. The tolerance region is a 6 Mbp region of bovine chromosome 15, 15:45 Mbp - 51 Mbp, which comprises at least one allele associated with at least one linkage disequilibrium block.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Davies, Michael
Tachella, Julian Andrés
Sheehan, Michael P
Abrégé
A sensor device (10) for photon-based imaging comprising one or more photon detectors configured to produce a plurality of photon detection signals in response to a plurality of photon detection events, wherein each photon detection event has a corresponding detection time and wherein the detection times of the plurality of photon detection events are distributed in accordance with a distribution over time; and processing circuitry configured to perform a sketching process using timing information of the plurality of photon detection events to obtain a compressed representation of the distribution over time, wherein the sketching process comprises: generating a plurality of feature values based on the timing information of the plurality of photon detection events using one or more feature functions; combining the generated plurality of feature values to obtain the compressed representation of the distribution over time, wherein the feature functions have one or more properties such that combining the plurality of feature values generated using the one or more feature functions preserves signal information and/or supresses background information and/or distinguishes signal information from background information in the compressed representation, wherein the compressed representation is such that at least one or more desired parameters of the distribution over time can be estimated by performing a parameter estimation process using the compressed representation, wherein the parameter estimation process is based on a model of the distribution over time.
G01S 7/4865 - Mesure du temps de retard, p.ex. mesure du temps de vol ou de l'heure d'arrivée ou détermination de la position exacte d'un pic
G01S 7/487 - Extraction des signaux d'écho désirés
G01S 17/10 - Systèmes déterminant les données relatives à la position d'une cible pour mesurer la distance uniquement utilisant la transmission d'ondes à modulation d'impulsion interrompues
H03M 7/30 - Compression; Expansion; Elimination de données inutiles, p.ex. réduction de redondance
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Pollard, Steven
Koeber, Ute
Matjusaitis, Mantas
Abrégé
The disclosure relates to synthetic super-enhancers activated by one or more transcription factors. In particular, the present disclosure describes synthetic super-enhancers that are activated by one or more transcription factors expressed in a target cell and used to express transgenes, such as adverse payloads, upon activation of the synthetic super-enhancer by the transcription factor(s).
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Strange, Calum David
Dos Reis, Goncalo Jose Nunes
Abrégé
A method implemented by a data processing apparatus and an associated data processing apparatus for predicting future condition parameter degradation. The method comprising: predicting a subset, a majority or all of a future condition parameter degradation curve of a cell from data from at least part of a charge-discharge cycle of the cell, a full charge-discharge cycle of the cell, or features extracted therefrom, using a machine learning process.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Rosser, Susan J.
Kleinjan, Dirk-Jan
Abrégé
The present disclosure relates to the modification of Chinese hamster ovary (CHO) cells at specific genomic loci that bestows the capability of receiving and expressing exogenous nucleic acid, for an extended period, as well as to methods of modifying the genome of a (CHO) cell, such that an exogenous nucleic acid sequence can be introduced, maintained and expressed by the modified CHO cell, for an extended period.
G01N 3/08 - Recherche des propriétés mécaniques des matériaux solides par application d'une contrainte mécanique par application d'efforts permanents de traction ou de compression
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Henderson, Robert
Al Abbas, Tarek
Finkelstein, Hod
Abrégé
A Light Detection and Ranging (LIDAR) detector circuit includes one or more photodetector elements configured to output respective detection signals indicating respective detection events responsive to light incident thereon, and at least one control circuit. The at least one control circuit is configured to receive the respective detection signals from the one or more photodetector elements, and to reset the one or more photodetector elements responsive to a transition of a clock signal after the respective detection events. Related memory devices and systems are also discussed.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Safari, Majid
Huang, Shenjie
Abrégé
A receiving device (12) for receiving an optical communication signal, wherein the optical communication signal comprises an encoded or modulated signal, the device comprising: one or more photodetectors (12) configured to produce photodetector signals in response to detecting photons; one or more further photodetectors (14) configured to produce further photodetector signals; a controller (16) configured to select an operational mode of the receiving device in dependence on at least a light level, wherein the operational mode is one of at least a first mode in which a demodulation or decoding process is performed on the photodetector signals and a second mode in which the demodulation or decoding process is performed on the further photodetector signals, and a photon count limiter (18) associated with the one or more photodetector for controlled limiting of the photon count of the one or more photodetectors in dependence on at least a light level.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Caporale, Salvatore
Storrar, David
Finkelstein, Hod
Al Abbas, Tarek
Henderson, Robert
Abrégé
A Time of Flight (ToF) system includes an emitter array comprising one or more emitters configured to emit optical signals, a detector array comprising a plurality of detectors that are configured to output respective detection signals responsive to the optical signals that are reflected from a target, and a control circuit. The control circuit is configured to: control the emitter array to emit a first optical signal; and provide a plurality of activation signals to a subset of the plurality of detectors responsive to the first optical signal to activate respective ones of the detectors of the subset for a first duration to generate detection signals associated with the first optical signal. Respective ones of the plurality of activation signals are offset from one another by respective time offsets.
G01S 7/4863 - Réseaux des détecteurs, p.ex. portes de transfert de charge
G01S 7/4865 - Mesure du temps de retard, p.ex. mesure du temps de vol ou de l'heure d'arrivée ou détermination de la position exacte d'un pic
G01S 7/487 - Extraction des signaux d'écho désirés
G01S 17/10 - Systèmes déterminant les données relatives à la position d'une cible pour mesurer la distance uniquement utilisant la transmission d'ondes à modulation d'impulsion interrompues
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Cobb, Stuart Robert
Ross, Paul
Hector, Ralph David
Abrégé
A system to limit the expression of a vector-derived transgene within a window that alleviates the disease-causing genetic deficiency without producing overexpression toxicity is described. This provides for 'dosage-insensitivity', whereby cells or tissues receiving more vector-derived transgene are disproportionately suppressed through an in-built single gene circuit that can regulate adaptively.
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
47.
THREE-DIMENSIONAL NANOSTRUCTURES CREATED BY ELECTROSPINNING
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Vong, Michel
Radacsi, Norbert
Nuansing, Wiwat
Abrégé
A method of manufacturing self-standing three-dimensional (3D) objects made of nanofibers is provided. Polyacrylonitrile (PAN), polyvinylpyrrolidone (PVP), Polycaprolactone (PCL), Cellulose Acetate (CA), and Polyvinylidene fluoride (PVDF) were produced as macroscopic 3D objects by 3D electrospinning printing (combination of 3D printing and electrospinning). In particular, the production of 3D carbon nanostructures was achieved by electrospinning polyacrylonitrile (PAN) nanofiber then the carbonising or calcination of the produced 3D nanofiber, in particular the 3D polyacrylonitrile (PAN) nanofiber.
D01D 5/00 - Formation des filaments, fils ou similaires
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p.ex. modélisation par dépôt de fil en fusion [FDM]
D01F 9/14 - Filaments de carbone; Appareils spécialement adaptés à leur fabrication par décomposition de filaments organiques
B29C 64/30 - Opérations ou équipements auxiliaires
B29C 64/371 - Conditionnement de l’environnement en utilisant un environnement autre que l’air, p.ex. un gaz inerte
B28B 1/00 - Fabrication d'objets façonnés à partir du matériau
H01M 4/1393 - Procédés de fabrication d’électrodes à base de matériau carboné, p.ex. composés au graphite d'intercalation ou CFx
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
48.
ENHANCED MITOCHONDRIAL RESPONSE WITH THIOZOLIDINEDIONE, PIOGLITAZONE OR ROSIGLITAZONE
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Licht-Mayer, Simon
Mahad, Don
Campbell, Graham
Chandran, Siddharthan
Abrégé
There is provided a method of targeting mitochondrial biogenesis and mitochondrial transport from the cell body to axon to protect acutely demyelinated axons from degeneration. The method may comprise increasing mobilization of mitochondria from the neuronal cell body to the demyelinated axon to treat demyelinating disorders and provide a novel neuroprotective strategy for vulnerable acutely demyelinated axons. The method may comprise mitochondrial biogenesis in the demyelinated axon to treat demyelinating disorders and provide a novel neuroprotective strategy for vulnerable acutely demyelinated axons. The method comprises a variety of compounds and strategies for increasing mitochondrial transport and biogenesis to the demyelinated axon in both the peripheral and central nervous systems.
A61K 31/385 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant plusieurs atomes de soufre dans le même cycle
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
49.
APPARATUS AND METHODS FOR WIRELESS DATA COMMUNICATION USING SPECTRUM WHITE SPACES
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Marina, Mahesh Kumar
Kassem, Mohamed Mostafa
Kheirkhah Sabetghadam, Morteza
Abrégé
There is described a computer implemented method for efficient aggregation of a Television White Space (TVWS) spectrum for backhaul use, said method comprising; providing a TVWS conversion substrate with a single antenna for combining multiple non-contiguous chunks of TVWS spectrum with said single antenna; providing a Multi- Path transport protocol; and providing an uncoupled, cross-layer congestion control algorithm for Multi-path Transmission Control Protocol (MPTCP).
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Doudesis, Dimitrios
Lee, Kuan Ken
Mills, Nicholas Linton
Abrégé
There is provided a method, systems and device to provide an indication of the probability of acute heart failure in a subject / individual. Suitably a device, systems and methods to determine a likelihood score based upon the concentration of natriuretic peptides in blood and at least two other clinical parameters. The method of determining acute heart failure can comprise the steps of combining the level of natriuretic peptide in a sample from an individual with at least two other clinical parameters from the individual in a statistical model to compute the probability of acute heart failure for the individual patient wherein the level of natriuretic peptide is provided as a continuous variable in the model.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Robertson, Neil
Li, Tianyue
Roy, Kingshuk
Ogale, Satishchandra
Abrégé
This invention relates to an electrode comprising (a) as an anion, a halide of either bismuth or antimony, wherein the halide is bromide or iodide, and (b) a cation. The invention also relates to a sodium ion or lithium ion battery comprising the electrode, and a laptop, mobile phone, electric vehicle or grid storage system comprising the sodium ion or lithium ion battery. In addition, the invention relates to a method of making the electrode comprising the steps of: (a) preparing a first solution comprising a halide of either bismuth or antimony, wherein the halide is bromide or iodide, (b) preparing a second solution comprising a cation, (c) mixing the first and second solutions, and (d) drying the resulting product.
H01M 4/136 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p.ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
H01M 4/1397 - Procédés de fabrication d’électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p.ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p.ex. phosphates, silicates ou borates
H01M 10/054 - Accumulateurs à insertion ou intercalation de métaux autres que le lithium, p.ex. au magnésium ou à l'aluminium
H01M 4/02 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p.ex. liants, charges
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Forbes, Stuart
Campana, Lara
Dwyer, Benjamin
Campbell, John
Fraser, Alasdair
Abrégé
The improved 4-5 day, optionally 3-5 day GMP-compliant in-vitro method enables the production of macrophages from monocytes that benefits from a shorter cell culture time, fewer interventions whilst maintaining the desired characteristics of the human macrophages. The present invention describes a method wherein the monocytes are cultured in medium comprising one or more growth factors to stimulate macrophages with a pro-regenerative phenotype. The method described herein is xeno-free, serum-free and GMP compliant. In addition, further disclosed are macrophages produced according to the present invention and the use of said macrophages in the treatment of liver diseases, such as liver cirrhosis.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Forbes, Stuart
Campana, Lara
Dwyer, Benjamin
Starkey Lewis, Philip
Campbell, John
Fraser, Alasdair
Abrégé
The development of the method of the invention enables the efficient and reproducible production of genetically modified GMP-grade human macrophages. The inventors have described the effects of the method described on cell viability and efficiency of introduction of genetic material into macrophages. Unlike previous methods of introducing genetic material into macrophages, excellent conditions are demonstrated which produce efficient transgene expression, without compromising cell viability. Critically, the method of the invention does not use virus to introduce genetic material, is efficacious on mature cells, are functional with in vitro assay and in vivo transfer in a liver disease model and complies with practices compatible with manufacture and delivery of these cells to patients.
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p.ex. magnétisme, ondes sonores
UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Forbes, Stuart
Campana, Lara
Dwyer, Benjamin
Campbell, John
Fraser, Alasdair
Abrégé
The present invention relates to a method of improving the viability of macrophages subjected to cryopreservation, particularly for macrophages which are to be used in therapy, wherein the method comprises a step of maintaining the macrophages at a temperature of 2-12°C for at least 30 minutes during either freezing or thawing procedures. Following the holding step during cooling, a cooling rate of 1 to 5°C is used until the macrophages in a medium are frozen. For thawing the macrophages, a warming rate of 1 to 5°C per minute is used until a temperature of 35-37°C is reached. The present invention further relates to the cryopreserved macrophages, and the thawed macrophages produced by such methods. The technique may provide macrophages that are GMP-compliant and have a viability of at least 60%.
UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
MERCK PATENT GMBH (Allemagne)
Inventeur(s)
Fleetwood-Walker, Susan
Mitchell, Rory
Abrégé
The invention relates to pharmaceutical combinations of ErbB1 and ErbB2 inhibitors, and the use of such combinations for the treatment of neuropathic pain.
A61K 31/517 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinazoline, périmidine
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Zhang, Chaoyun
Patras, Paul
Fiore, Marco
Abrégé
To be able to adequately provide desired services over a 5G mobile service network, the 5G communication infrastructures requires a much-improved flexibility in resource management. Network operators are foreseen to deploy network slicing, by isolating dedicated resources and providing customised logical instances of the physical infrastructure to each service. A critical operation in performing management and orchestration of network resources is the anticipatory provisioning of isolated capacity to each network slice. Accordingly, it is necessary to obtain an estimate of service level demands. However, the estimation of such service level demands is typically obtained via deep packet inspection, which is a resource intensive and time-consuming process. Therefore, it is typically not possible to provide updated accurate estimates at a frequency suitable for use in accurate prediction of a future per-service traffic consumption, without an undesirable level of computational and time resources being required. The present invention provides a distributed network traffic data decomposition method which makes use of a neural network to provide an accurate future per-service traffic consumption prediction without deep-packet inspection or another resource intensive analysis method.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
HERIOT-WATT UNIVERSITY (Royaume‑Uni)
Inventeur(s)
Hands, Philip James Walton
Mitrakos, Vasileios
Macintyre, Lisa Mirian
Desmulliez, Marc Philippe Yves
Abrégé
There is described a method of producing a flexible structure and sensor devices incorporating the former, such as wireless LC sensors, that comprises a plurality of thin-film layers of elastomeric material and at least one layer of micro-wrinkled electrically conductive material. The method includes steps leading to 2D wrinkled metallised polydimethylsiloxane (PDMS) layers enabling considerable flexibility with negligible bending failure for angles up to 180 degrees.
H05K 1/16 - Circuits imprimés comprenant des composants électriques imprimés incorporés, p.ex. une résistance, un condensateur, une inductance imprimés
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
G01L 9/00 - Mesure de la pression permanente, ou quasi permanente d’un fluide ou d’un matériau solide fluent par des éléments électriques ou magnétiques sensibles à la pression; Transmission ou indication par des moyens électriques ou magnétiques du déplacement des éléments mécaniques sensibles à la pression, utilisés pour mesurer la pression permanente ou quasi permanente d’un fluide ou d’un matériau solide fluent
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Henderson, Robert
Finkelstein, Hod
Abrégé
A Light Detection and Ranging (LIDAR) detector circuit includes a memory device comprising a non-transitory storage medium that is configured to store data indicative of detection events in respective memory bins, and at least one control circuit. The at least one control circuit is configured to receive detection signals from one or more photodetector elements, identify a presence or an absence of detection events indicated by the detection signals during a portion of time between pulses of an emitter signal output from a LIDAR emitter element, and execute one of a first memory operation or a second memory operation to update the data in the respective memory bins responsive to identification of the presence or the absence of the detection events, respectively. Related circuits and methods of operation are also discussed.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Henderson, Robert
Al Abbas, Tarek
Storrar, David
Abrégé
A Light Detection and Ranging (LIDAR) detector circuit includes a memory device comprising a first memory and a second memory, and at least one control circuit. The at least one control circuit is configured to execute first memory storage operations to store data indicated by detection signals received from one or more photodetector elements in the first memory during a first portion of a time between pulses of an emitter signal output from a LIDAR emitter element, and to execute second memory storage operations to include the data, which was stored in the first memory, in the second memory during a second portion of the time between the pulses of the emitter signal. Related devices and methods of operation are also discussed.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Finkelstein, Hod
Henderson, Robert
Al Abbas, Tarek
Storrar, David
Abrégé
A Light Detection and Ranging (lidar) system, includes an emitter configured to emit a plurality of optical signals, a detector configured to be activated to detect one of the optical signals in light that is incident on the detector and to provide count data corresponding to the one of the optical signals that were detected, a plurality of storage memory locations configured to store the count data therein, and a control circuit configured to change a location at which the count data is stored from a first storage memory location to a second storage memory location based on an elapsed time duration from an emission of the one of the optical signals.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Al Abbas, Tarek
Calder, Neil
Henderson, Robert
Finkelstein, Hod
Abrégé
A Light Detection and Ranging (LIDAR) system includes an emitter array comprising a plurality of emitter units operable to emit optical signals, a detector array comprising a plurality of detector pixels operable to detect light for respective strobe windows between pulses of the optical signals, and one or more control circuits. The control circuit(s) are configured to selectively operate different subsets of the emitter units and/or different subsets of the detector pixels such that a field of illumination of the emitter units and/or a field of view of the detector pixels is varied based on the respective strobe windows. Related devices and methods of operation are also discussed.
G01S 17/894 - Imagerie 3D avec mesure simultanée du temps de vol sur une matrice 2D de pixels récepteurs, p.ex. caméras à temps de vol ou lidar flash
G01S 17/89 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour la cartographie ou l'imagerie
G01S 17/10 - Systèmes déterminant les données relatives à la position d'une cible pour mesurer la distance uniquement utilisant la transmission d'ondes à modulation d'impulsion interrompues
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
NIKLAS ARNBERG KONSULT AB (Suède)
Inventeur(s)
Custers, Jerôme Hubertina Henricus Victor
Havenga, Menzo Jans Emko
Ballman, Mónika
Lemckert, Angelique Alida Corina
Baker, Andrew
Arnberg, Niklas
Kajan, Gyozo
Abrégé
Provided herein are chimeric adenoviral vectors. The provided chimeric adenoviral vectors can be used to induce a protective immune response and/or express a transgene in a subject in need thereof.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Rambukkana, Anura
Abrégé
There are disclosed biomarkers for use in the detection and diagnosis of M. leprae which is the causative organism for leprosy. Further, the present invention provides diagnostic methods and treatment methods for leprosy.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Wang, Baojun
Liu, Yang
Abrégé
There is provided a novel, eukaryote-like bacterial CRISPRa system based on δ54- dependent promoters, which supports long-distance, and hence multi-input regulation with unprecedented high dynamic ranges. Also provided is a CRISPRa system that can activate δ54-dependent promoters and supports orthogonal gene regulation on multiple levels. Additionally, there is provided the construction of cascaded CRISPRa circuits and a reusable scanning platform for optimizing metabolic pathways.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Buck, Amy
Neophytou , Kyriaki
Abrégé
There is discussed nematode antigens capable of causing an immune response in a host such that a protective effect is provided to the host in relation to the nematode. Antigens, compositions for the treatment of parasitic nematode infections, methods of prophylaxis and treatment of parasitic nematode infections, and vaccines to reduce and / or control parasitic nematode infections are provided.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Mccormick, Alistair James
Atkinson, Nicola Jane
Abrégé
Aspects of the present disclosure relate to genetically altered plants having a modified Rubisco and further having a modified Essential Pyrenoid Component 1 (EPYC1) for formation of an aggregate of modified Rubisco and EPYC1 polypeptides. Other aspects of the present disclosure relate to methods of making such plants as well as cultivating these genetically altered plants.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Vervelde, Apolonia
Nash, Esther Jane
Abrégé
There is provided an in vitro three dimensional cell construct for use as a model of the avian intestine derived from avian intestinal tissue comprising avian cells organised into intestinal villi and crypts. Suitably the construct comprises an exterior surface that mimics the apical surface of a chicken intestine. Also provided are methods of making the cell construct and use of the construct as an in vitro intestinal model system to examine an agent including, but not limited to a microbe, a vaccine, a pharmaceutical, a feed additive, a toxin, a pre-biotic, post-biotic, pre pro post biotic, therapeutic, a cell, gene construct, protein, immune-modulator, an intestinal effector agent, a candidate intestinal effector agent, cell signalling inhibitor, or cell signalling activator.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Wood, Dr Tiffany
Katyan, Navneeta
Abrégé
This invention relates to a gel comprising a colloid dispersed in a lyotropic nematic liquid crystal, the lyotropic nematic liquid crystal comprising defect lines formed by the colloid. The invention also relates to a method for making the gel comprising the steps of: (a) mixing a nematogen with a liquid and the colloid to form a resulting dispersion, and (b) applying shear to the resulting dispersion at a temperature such that a lyotropic nematic liquid crystal phase is formed. In addition, the invention relates to an adhesive, lubricant, ceramic, film, spray, gel, lotion, foam, nanowire, yarn, medical implant, wearable, bone graft material, 3D printing material, ink, agrochemical formulation, topical formulation, paint, coating, composite, energy storage material, advanced material, responsive composite, cosmetic product, personal care product, pharmaceutical or foodstuff comprising the gel.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Walmsley, Sarah
Whyte, Moira
Forbes, Stuart
Mirchandani Thanwerdas, Ananda
Jenkins, Stephen
Abrégé
The present invention relates to an agent for increasing mononuclear cell number, and/or inducing a pro-restorative phenotype in mononuclear cells for use in the treatment of a lung disease associated with dysfunctional neutrophilic inflammation, particularly wherein the agent is CSF1 and the lung disease is acute respiratory distress syndrome (ARDS).
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Henderson, Robert
Finkelstein, Hod
Abrégé
A Time of Flight (TOF) system includes an incrementing circuit and a plurality of pixels. Each pixel includes a plurality of detectors configured to output respective detection signals responsive to detection of a plurality of photons incident thereon and a shared memory configured to store a respective count of the photons incident on each of the plurality of detectors. The incrementing circuit is configured to update the respective count for each of the plurality of detectors in the shared memory based on the respective detection signals.
G01S 17/00 - Systèmes utilisant la réflexion ou la reradiation d'ondes électromagnétiques autres que les ondes radio, p.ex. systèmes lidar
G01S 17/08 - Systèmes déterminant les données relatives à la position d'une cible pour mesurer la distance uniquement
G01S 17/10 - Systèmes déterminant les données relatives à la position d'une cible pour mesurer la distance uniquement utilisant la transmission d'ondes à modulation d'impulsion interrompues
G01S 17/89 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour la cartographie ou l'imagerie
71.
SMALL MOLECULE PHOTOSENSITIZERS FOR PHOTODYNAMIC THERAPY
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Vendrell, Marc
Fernandez, Antonio
Benson, Sam
Barth, Nicole, D.
De Moliner, Fabio
Abrégé
The invention relates to small photosensitizers, their process of preparation and uses of the compounds in optical imaging and photodynamic therapy. The invention provides a compound of formula (I), a derivative or a salt thereof Wherein R1 is selected from the group consisting of amines, anilines, phenols, thiophenols, selenols and aryl groups; R2 and R3 independently are H or halogen; R4 is selected from the group consisting of H, nitre and cyano: and R5 and R6 independently are either absent or oxygen or methyl.
C07D 421/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de sélénium, de tellure ou d'halogènes comme hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/095 - Composés du soufre, du sélénium ou du tellure, p.ex. thiols
72.
SMALL TUNABLE FLUOROPHORES FOR THE DETECTION AND IMAGING OF BIOMOLECULES
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Vendrell, Marc
Fernandez, Antonio
Benson, Sam
Barth, Nicole D.
De Moliner, Fabio
Abrégé
The invention relates to small, conjugatable, orthogonal and tunable fluorophores for imaging of small bioactive molecules. The invention further relates to processes for the preparation of the compounds, and uses of the compounds in therapeutic, diagnostic, surgery and analytical applications. The invention provides a compound of formula (I), a derivative or a salt thereof. Wherein X is selected from the group consisting of NH, O, S, SeR5R6, CR7R8; R1 is selected from the group consisting of amines, alcohols, thiols, thiophenols, selenols, selenophenols and aryl groups; R2 and R3 are independently H or a halogen; R4 is either H, nitro or cyano; R5 is either absent or methyl or oxygen; R6 is either absent or methyl or oxygen; and R7 and R8 are independently selected from the group consisting of linear or cyclic alkyl groups containing halogen, amino, cyano or carboxylic ester substituents, and alkyl aryl groups.
C09B 23/01 - Colorants méthiniques ou polyméthiniques, p.ex. du type cyanine caractérisés par la chaîne méthinique
C09B 23/04 - Colorants méthiniques ou polyméthiniques, p.ex. du type cyanine caractérisés par la chaîne méthinique contenant un nombre impair de groupes CH un seul groupe CH, p.ex. cyanines, isocyanines, pseudocyanines
C07D 421/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de sélénium, de tellure ou d'halogènes comme hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF AGRICULTURE (USA)
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Kapczynski, Darrell, R.
Digard, Paul
Vervelde, Lonneke
Suarez, David, L.
Abrégé
The disclosure relates to mutant recombinant influenza virus gene segment 7 with at least one mutation that modulates expression of M2 and M42 polypeptide. Also disclosed are recombinant influenza viruses comprising the mutant influenza virus gene segment 7, compositions comprising the mutant recombinant influenza virus gene segment 7, use of such mutant recombinant influenza virus gene segment 7 and mutant recombinant Influenza viruses.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Henderson, Robert
Al Abbas, Tarek
Calder, Neil
Finkelstein, Hod
Abrégé
A Light Detection And Ranging (LIDAR) detector circuit includes a plurality of detector pixels, where each or a respective detector pixel of the detector pixels includes a plurality of detector elements. At least one control circuit is configured to provide one or more detector control signals that selectively activate one or more of the detector elements of the respective detector pixel to define a first active detection area including a first subset of the detector elements for a first image acquisition, and a second active detection area including a second subset of the detector elements for a second image acquisition. Related devices and methods of operation are also discussed.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Pollard, Jeff
Cassetta, Luca
Fragkogianni, Stamatina
Abrégé
The present invention relates to the field of breast cancer diagnosis and treatment. The present invention provides methods comprising a) analysing a biological sample obtained from a subject to determine the presence of target molecules representative of expression of at least two biomarkers selected from the group listed in Table 1, wherein the biological sample is a breast tissue sample or derivative thereof; and b) comparing the expression levels of the biomarkers determined in (a) with one or more reference values, wherein whether there is a difference in the expression of the biomarkers in the sample from the subject compared to the one or more reference values is indicative of a clinical indication.. The invention further provides methods of treatment and kits and assays for use in the methods of the invention.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Pollard, Jeff
Cassetta, Luca
Fragkogianni, Stamatina
Abrégé
SIGLEC1CCL8SIGLEC1CCL8SIGLEC1CCL8CCL8 in the sample from the subject or not compared to the one or more reference values is indicative of a clinical indication. The invention further provides related methods for treatment of cancer, kits and assay devices for use in the methods, and methods for identifying molecules for use in treating cancer.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
77.
STROBE WINDOW DEPENDENT ILLUMINATION FOR FLASH LIDAR
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Henderson, Robert
Al Abbas, Tarek
Calder, Neil
Finkelstein, Hod
Abrégé
A Light Detection And Ranging (LIDAR) system includes one or more emitter elements configured to emit optical signals responsive to respective emitter control signals, one or more detector elements configured to detect incident photons for respective strobe windows of operation between pulses of the optical signals and at respective delays that differ with respect to the pulses, and at least one control circuit. The at least one control circuit is configured to generate the respective emitter control signals to differently operate the one or more emitter elements based on the respective strobe windows of operation of the one or more detector elements.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Henderson, Robert
Al Abbas, Tarek
Calder, Neil
Abrégé
A Light Detection and Ranging (LIDAR) measurement circuit includes an array of single photon detectors configured to detect photons responsive to emission of an optical signal from an emitter, and a pixel processing circuit that is configured to calculate an estimated time of arrival of photons incident on the array of single photon detectors by utilizing a plurality of coarse histogram bins. Respective ones of the plurality of coarse histogram bins are associated with a duration that is greater than one-sixteenth of a pulse width of the optical signal.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Morrison, Liam
Grey, Finn
Steketee, Pieter
Chiweshe, Stephen
Abrégé
bruceicongolensevivaxvivax wherein detecting the presence of the excreted / secreted small RNA derived from the non-coding 7SL RNA of the peptide signal recognition particle is indicative infection of trypanosome in the host.
C12Q 1/6893 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les protozoaires
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (Royaume‑Uni)
Inventeur(s)
Mcgrew, Mike
Sang, Helen
Isaiah Idoko-Akoh, Alewo
Barclay, Wendy
Long, Jason
Abrégé
The present invention relates to genome modified birds adapted to be resistant to influenza virus infection, methods of generating such birds, and nucleotides and polypeptides for use in such methods
C07K 14/44 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de protozoaires
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Henderson, Robert
Finkelstein, Hod
Abrégé
A Light Detection And Ranging (LIDAR) measurement circuit includes a processor circuit that is configured to receive detection signals output from a plurality of detector elements in response to a plurality of photons incident thereon during a detection window, identify detection events based on the detection signals, and calculating an estimated time of arrival of the plurality of photons based on a sum of respective numbers of the detection events that have been identified at respective time intervals of the detection window. The processor circuit may include at least one accumulator circuit that is configured to output the sum of the respective numbers of the detection events that have been identified at the respective time intervals based on a counter signal that is incremented responsive to each of the detection events, and a clock signal corresponding to the respective time intervals.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Henderson, Robert
Finkelstein, Hod
Calder, Neil
Al Abbas, Tarek
Abrégé
A Light Detection and Ranging (lidar) apparatus includes an emitter array comprising a plurality of emitter units configured to emit optical signals responsive to respective emitter control signals, a detector array comprising a plurality of detector pixels configured to be activated and deactivated for respective strobe windows between pulses of the optical signals; and a control circuit configured to provide a strobe signal to activate a first subset of the detector pixels while leaving a second subset of the detector pixels inactive.
G01S 7/48 - DÉTERMINATION DE LA DIRECTION PAR RADIO; RADIO-NAVIGATION; DÉTERMINATION DE LA DISTANCE OU DE LA VITESSE EN UTILISANT DES ONDES RADIO; LOCALISATION OU DÉTECTION DE LA PRÉSENCE EN UTILISANT LA RÉFLEXION OU LA RERADIATION D'ONDES RADIO; DISPOSITIONS ANALOGUES UTILISANT D'AUTRES ONDES - Détails des systèmes correspondant aux groupes , , de systèmes selon le groupe
G01S 17/00 - Systèmes utilisant la réflexion ou la reradiation d'ondes électromagnétiques autres que les ondes radio, p.ex. systèmes lidar
G01S 17/06 - Systèmes déterminant les données relatives à la position d'une cible
G01S 17/88 - Systèmes lidar, spécialement adaptés pour des applications spécifiques
G01S 17/95 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour la météorologie
83.
GENETICALLY MODIFIED STERILE AVIANS AND METHOD FOR THE RECONSTITUTION THEREOF
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Mcgrew, Mike
Woodcock, Mark
Abrégé
Disclosed herein transgene construct comprising (i) a first nucleotide sequence, wherein the activity of the protein encoded by said first nucleotide sequence causes death of germ cells in the presence of an exogenous induction agent and (ii) a second nucleotide sequence which targets said construct to avian germ cells, methods of using the same and a transgenic avian provided by such methods.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Michel, Julien
De Simone, Alessio
Ioannidis, Charalampos
Juarez-Jimenez, Jordi
Georgiou, Charis
Gupta, Arun
Hulme, Alison
Walkinshaw, Malcolm
Doughty Shenton, Dahlia
Abrégé
The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof useful as inhibitors of Cyclophilins and modulators of cyclophilin-like proteins. The invention also relates to uses of said compounds in the treatment of various disorders. Formula (I), wherein: R1and R2are each independently is selected from the group consisting of -R, -haloalkyl, -hydroxyalkyl, -OR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, and - N(R)2; wherein R21-63-103-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, sulphur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms selected from nitrogen, oxygen, or sulphur; R3is Formual (Ia) selected from the group consisting of -OEt, and wherein R5and R6are independently selected from the group consisting of H, halide, methoxy, thiomethyl, morpholine and trifluoromethyl;R41-61-6-alkyl-, and R4.122- wherein, R4.13-63-6-cycloalkyl-, a 5-6 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, sulphur; optionally substituted with one R4.1.1wherein, R4.1.11-422and Formula (Ib), wherein ring B is a fused 5-10 membered saturated or partially unsaturated heterocyclic mono- bicyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen or sulphur, which is optionally substituted by -OH; and m is 1 or 2; and n is 1 or 2.
C07C 275/16 - Dérivés d'urée, c. à d. composés contenant l'un des groupes les atomes d'azote ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes urée liés à des atomes de carbone acycliques d'un squelette carboné acyclique et saturé étant substitué de plus par des groupes carboxyle
C07D 207/08 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés, substitués par des hétéro-atomes, liés aux atomes de carbone du cycle
C07D 257/06 - Cycles à cinq chaînons avec des atomes d'azote liés directement à l'atome de carbone du cycle
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Vendrell, Marc
Fernandez, Antonio
Mellanby, Richard
Scott, Jamie
Mair, Iris
Guzman, Claudia, Garcia
Dhillon, Baljean
Bagnaninchi, Pierre
Abrégé
NN-triazoles family of bright, photostable and cell- permeable NIR chromophores containing neutral triazole groups. In particular, a compound of formula (I), a derivative or a salt thereof is provided. Formula (I) wherein, R1 is absent or selected from the group consisting C1-C6 alkyl, and C1-C9 alkyl substituted with one or more of the following groups: halogen, hydroxyl, aryl, carboxylic acids; C3-C6 cycloalkyl, aryl groups substituted with one or more of the following groups: alkyl, cycloalkyl, naphthalenyl, phenanthrenyl, amino, aminoalkyl, aminocycloalkyl, formyl, trifluoromethyl, carboxyl, halogen, hydroxyl, hydroxyalkyl, alkyloxy, hydroxyaryl, nitro; thiophenyl, pyridinyl, imidazolyl, acetal, benzyl; R2 and R3 are each independently selected from the group consisting of C1-C6 alkyl, and C1-C6 alkyl substituted with one or more of the following groups: carboxylic acids, substituted amides, sulphonate groups, aryl, succinimidyl esters, maleimides, polyethyleneglycol-based substituents; R4, R5, R8 and R9 are each independently absent, C1-C6 alkyl or H; R6 and R10 are each independently H; R7 and R11 are each independently selected from the group consisting of H, Me and sulphonate; or R6-R7 and/or R10-R11 form an aromatic ring and/or R5-R6 and/or R9-R10 form an aromatic ring; R12 is selected from the group consisting of H, C1-C6 alkyl, and C1-C9 alkyl substituted with one or more of the following groups: hydroxyl, aryl, carboxylic esters, carboxylic acids; amine, aminoalkyl, aminocycloalkyl, aminoaryl, tosyl, hydroxyalkyl, hydroxyaryl, thioalkyl, thioaryl; X and Y are each independently selected from the group consisting of C, S, O and N; and Z is either C or N. The invention further relates to processes for the preparation of the compounds, and uses of the compounds in therapeutic, diagnostic, surgery and analytical applications.
C09B 23/01 - Colorants méthiniques ou polyméthiniques, p.ex. du type cyanine caractérisés par la chaîne méthinique
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Lusby, Paul
Burke, Michael
Grantham, William
Archibald, Steve
Burke, Benjamin
Abrégé
46nn, where M is a transition metal ion having 6 d-shell valence electrons, X is a counter ion and n is the number of counterions such that the total charge of the compound of formula (I) is zero, and wherein L is a 5-(5-bipyridin-2,2'-yl)-2,2'-bipyridine or derivative thereof. Methods of preparing the compounds and uses of the compounds to retain radiolabels are also presented.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Wood, Harry A. C.
Stone, James M.
Harrington, Kerrianne
Abrégé
A method of forming an imaging fibre apparatus comprises: • arranging core rods 102 and cladding rods 104 to form at least one primary stack 100a, each primary stack 100a comprising a plurality of core rods 102 and cladding rods 104 arranged in a stack arrangement thereby to form a plurality of core regions within a cladding region; • performing a drawing process to form a plurality of drawn stacks from the at least one primary stack; • wherein the plurality of core rods and cladding rods are further arranged to have a selected shape such that the plurality of stacks stack together in a desired arrangement and wherein the stack arrangement comprises an at least partial outer layer of cladding rods thereby to provide separation between core regions of respective adjacent stacks when stacked in the desired arrangement, the method further comprising: • stacking the plurality of drawn stacks together in the desired arrangement to form a further stack; • drawing the further stack; and • using the drawn further stack to form an imaging fibre apparatus.
THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (Royaume‑Uni)
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Sutherland, Andrew
Pimlott, Sally
Tavares, Adriana
Lucatelli, Christophe
Abrégé
The invention provides a compound of formula (I), and salts, solvates and radiolabelled forms thereof, together with complexes of the compound of formula (I) with TSPO, and methods for forming such complexes, and methods for detecting the compound of formula (I), such as in complex with TSPO.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Robinson, Adam
Abrégé
There is provided a thermal energy storage system, comprising at least two thermal storage masses, wherein an inner thermal storage mass (48) is contained within an outer thermal storage mass (49). A pump or compressor (42) forces a compressible fluid around the system. A first storage mass heat exchanger (50) has a first side in fluid communication with the pump or compressor (42), and a second side in contact with the outer thermal storage mass (49). A second storage mass heat exchanger (51) has a first side in fluid communication with the first side of the first storage mass heat exchanger (50), and a second side in contact with the inner thermal storage mass (48). A turbine (43) has a turbine inlet in fluid communication with the first side of the second storage mass heat exchanger (51), and a turbine outlet. An electrical generator is driven by the turbine (43). The system further comprises a thermal store (52) containing a thermal store medium. At least one thermal input heat exchanger (55) is located in the thermal store (52), the at least one thermal input heat exchanger having a first side adapted to receive heat from the outer thermal storage mass (49), and a second side in contact with the thermal store medium. At least one thermal output heat exchanger (53) is also located in the thermal store (52), the at least one thermal output heat exchanger having a first side in fluid communication with a hot water and/or heating supply, and a second side in contact with the thermal store medium.
F01K 3/02 - Emploi d'accumulateurs et de machines motrices d'un type particulier; Leur commande
F01K 3/12 - Ensembles fonctionnels caractérisés par l'emploi d'accumulateurs de vapeur ou de chaleur ou bien de réchauffeurs intermédiaires de vapeur comportant plusieurs accumulateurs
F01K 3/18 - Ensembles fonctionnels caractérisés par l'emploi d'accumulateurs de vapeur ou de chaleur ou bien de réchauffeurs intermédiaires de vapeur comportant des réchauffeurs
F16K 11/065 - Soupapes ou clapets à voies multiples, p.ex. clapets mélangeurs; Raccords de tuyauteries comportant de tels clapets ou soupapes; Aménagement d'obturateurs et de voies d'écoulement spécialement conçu pour mélanger les fluides dont toutes les faces d'obturation se déplacent comme un tout comportant uniquement des tiroirs à éléments de fermeture glissant linéairement
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Abumarshoud, Hanaa
Haas, Harald
Abrégé
There is described a transmission processing system (32) of an optical wireless communication system (10). The processing system (32) is configured to receive an information-carrying signal s(t) and a sequencing signal GT(t). The processing system (32) is configured to configure at least one transmission resource (40a, 40b) to transmit information based on a condition being satisfied. The condition depends on a relationship between the information-carrying signal and the sequencing signal.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Caporali, Andrea
Miscianinov, Vladislav
Abrégé
Described herein are methods for the regulation of angiogenesis and endothelial to mesenchymal transition, the methods involving administration of modulators of miRNA-148b levels. Also described are the use of modulators of miRNA-148b levels in medical treatments such as the treatment of wounds, in particular soft tissue wounds.
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Mclean, Alec
Courtney, Margaret
Howard, Lynsey
Porteous, Steven
Collie, David
Mclachlan, Gerry
Abrégé
Methods of prophylactically treating fibrotic conditions using a synthetic lamellar body composition are provided, such as conditions of the lung, skin, gastrointestinal system, genitourinary system, heart, peritoneum, kidney, liver, and mucosa. In particular the present invention is concerned with lung injury which may be characterised by increased pulmonary vascular permeability. Suitably thelamellar body composition for use in the prophylactic treatment of fibrotic or pro-fibrotic conditionscomprises phosphatidylcholine, cholesterol and optionally at least one phospholipid selected from phosphatidyl serine, phosphatidyl glycerol and phosphatidyl inositol to provide an anionic lamellar body.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Forrester, Lesley
Lopez-Yrigoyen, Martha
Abrégé
The present invention relates to: an in vitro or ex vivo method of producing a population of human pluripotent stem cell derived macrophages or enucleated erythroid cells; human pluripotent stem cells derived macrophage comprising a KLF1 transgene and uses of human pluripotent stem cell derived macrophages or enucleated erythroid cells as well as being directed to IL-33 for use in the treatment of dyserythropoietic anaemia in a subject.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Kranc, Kamil Romuald
O'Carroll, Dónal
Abrégé
The present invention relates to modified haematopoietic stem cells, methods for preparing them, and their use in therapy; as well as methods and reagents for expanding haematopoietic stem cells (HSC) and methods for treating haematological disorders. A particular aspect relates to a method for treating a disease or condition characterised by elevated YTHDF2 expression comprising administering to a patient an effective amount of an YTHDF2 inhibitor. Certain aspects of the invention rely on YTFIDF2 protein level or function and use of YTFIDF2 inhibitors.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Forbes, Stuart
Campbell, John
Mcgowan, Neil W. A.
Fraser, Alasdair R.
Abrégé
The present invention relate to autologous isolated unpolarized human macrophages for use in the treatment of liver disease and macrophages for use in a method of treating fibrosis in a human in need thereof.
A61K 35/28 - Moelle osseuse; Cellules souches hématopoïétiques; Cellules souches mésenchymateuses de toutes origines, p.ex. cellules souches dérivées de tissu adipeux
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
96.
BRANCH TARGET BUFFER ARRANGEMENT FOR INSTRUCTION PREFETCHING
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Kumar, Rakesh
Grot, Boris
Nagarajan, Vijay
Abrégé
A branch target buffer, BTB, is provided to store at least one BTB entry corresponding to a respective branch in a control flow in a sequence of machine-readable instructions of a computer program. The BTB has a tag field to compare with a program counter of a fetch address generator and at least one further field to store information characteristic of the branch instruction identified by the corresponding tag field and allowing a conditional branch to be distinguished from an unconditional branch instruction. The BTB has a predetermined storage capacity and is utilized such that unconditional branch instructions are preferentially allocated storage space in the BTB relative to conditional branch instructions.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Dhaliwal, Kevin
Tanner, Michael G.
Thomson, Robert R.
Abrégé
A system comprises a medical device configured to be positioned at least partially within a scattering medium, the medical device comprising at least one optical fibre or other waveguide having a plurality of light-emitting regions arranged along at least part of the length of the at least one optical fibre or other waveguide; a pulsed light source configured to transmit pulsed light into a proximal end of the at least one optical fibre or other waveguide, such that the pulsed light is guided along the at least one optical fibre or other waveguide to the light-emitting regions and emitted by the light-emitting regions into the scattering medium; at least one detector configured to receive photons of the pulsed light that have passed through the scattering medium; and a processor configured to: select signals corresponding to at least some of the received photons; determine a respective location of each of the light-emitting regions based on the selected signals; and determine a path of at least part of the medical device based on the determined locations.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
A61B 1/06 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement
A61B 1/07 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement utilisant des moyens conduisant la lumière, p.ex. des fibres optiques
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Videv, Stefan
Haas, Harald
Abrégé
An apparatus (12) is connectable to a backbone for a network (10) comprising at least one other apparatus (12). The apparatus (12) comprises an optical communications access point or transceiver and is configured to receive optical communications signals and transmit optical communications signals. At least one of the received and transmitted optical communications signals is communicated via the at least one other apparatus (12) of the backbone.
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Walkinshaw, Malcolm D.
Pettit, Simon Neil
Highton, Adrian
Mcnae, Iain William
Abrégé
The invention described herein relates to compounds of formula I, or salts, hydrates and solvates thereof. (I) In other aspects the invention relates to pharmaceutical compositions comprising compounds defined herein, the use of the compounds defined herein in therapy, including for the treatment of a disease or condition mediated by infection by a protozoal parasite, such as trypanosomiasis.
A61P 33/02 - Antiprotozoaires, p.ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p.ex. kétorolac, physostigmine
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (Royaume‑Uni)
Inventeur(s)
Bradley, Mark
Owens, Matthew
Abrégé
The present invention relates to methods for isolating nucleic acids present in a sample, in particular cell-free DNA (cfDNA) from a blood sample and polymers, substrates and kits for the method. Polymers with characteristics suitable to bind such nucleic acids are provided.